tradingkey.logo

ImmuCell Corp

ICCC
5.970USD
-0.170-2.77%
收盘 12/19, 16:00美东报价延迟15分钟
54.00M总市值
21.77市盈率 TTM

ImmuCell Corp

5.970
-0.170-2.77%

关于 ImmuCell Corp 公司

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

ImmuCell Corp简介

公司代码ICCC
公司名称ImmuCell Corp
上市日期May 01, 1987
CEOte Boekhorst (Olivier)
员工数量69
证券类型Ordinary Share
年结日May 01
公司地址56 Evergreen Drive
城市PORTLAND
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编04103
电话12078782770
网址https://immucell.com/
公司代码ICCC
上市日期May 01, 1987
CEOte Boekhorst (Olivier)

ImmuCell Corp公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
215.75K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
133.43K
+1.24%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%
地区USD
名称
营收
占比
United States
4.87M
75.63%
Other
1.57M
24.37%
业务
地区
业务USD
名称
营收
占比
First Defense® product line
6.40M
99.28%
Other animal health
46.36K
0.72%

股东统计

更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
其他
68.00%
持股股东
持股股东
占比
Knudsen (Ejnar A III)
9.21%
Pessin (Norman H)
7.12%
Rothschild (Jonathan E)
5.68%
SRK Capital, LLC
5.55%
Pessin (Sandra F)
4.44%
其他
68.00%
股东类型
持股股东
占比
Individual Investor
32.25%
Investment Advisor
14.31%
Investment Advisor/Hedge Fund
3.60%
Hedge Fund
1.98%
Research Firm
0.02%
其他
47.84%

机构持股

更新时间: 10月5日 周日
更新时间: 10月5日 周日
报告期
机构数
持股数
持股占比
持股变动
2025Q3
46
1.81M
20.03%
-84.61K
2025Q2
56
4.25M
46.97%
-88.13K
2025Q1
59
4.81M
59.23%
+487.91K
2024Q4
58
4.30M
48.30%
+425.64K
2024Q3
56
4.25M
49.53%
+427.28K
2024Q2
57
3.67M
43.77%
+363.56K
2024Q1
55
3.19M
41.22%
-172.12K
2023Q4
55
3.22M
41.55%
-93.50K
2023Q3
57
3.23M
41.67%
-83.77K
2023Q2
56
3.25M
41.94%
-58.60K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Knudsen (Ejnar A III)
463.62K
5.13%
--
--
Apr 14, 2025
Pessin (Norman H)
644.02K
7.12%
--
--
Apr 14, 2025
Rothschild (Jonathan E)
514.00K
5.68%
--
--
Apr 14, 2025
SRK Capital, LLC
502.26K
5.55%
--
--
Apr 14, 2025
Pessin (Sandra F)
401.82K
4.44%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
308.70K
3.41%
+83.11K
+36.84%
Jun 30, 2025
Brigham (Michael F)
215.75K
2.39%
--
--
Apr 14, 2025
Renaissance Technologies LLC
159.99K
1.77%
+26.00K
+19.40%
Jun 30, 2025
Pessin (Brian L)
136.88K
1.51%
--
--
Apr 14, 2025
Tomsche (David Scott)
131.80K
1.46%
+24.37K
+22.69%
Apr 14, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
占比0.01%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

ImmuCell Corp的前五大股东是谁?

ImmuCell Corp 的前五大股东如下:
Knudsen (Ejnar A III)持有股份:463.62K,占总股份比例:5.13%。
Pessin (Norman H)持有股份:644.02K,占总股份比例:7.12%。
Rothschild (Jonathan E)持有股份:514.00K,占总股份比例:5.68%。
SRK Capital, LLC持有股份:502.26K,占总股份比例:5.55%。
Pessin (Sandra F)持有股份:401.82K,占总股份比例:4.44%。

ImmuCell Corp的前三大股东类型是什么?

ImmuCell Corp 的前三大股东类型分别是:
Knudsen (Ejnar A III)
Pessin (Norman H)
Rothschild (Jonathan E)

有多少机构持有ImmuCell Corp(ICCC)的股份?

截至2025Q3,共有46家机构持有ImmuCell Corp的股份,合计持有的股份价值约为1.81M,占公司总股份的20.03%。与2025Q2相比,机构持股有所增加,增幅为-26.94%。

哪个业务部门对ImmuCell Corp的收入贡献最大?

在FY2025Q2,First Defense® product line业务部门对ImmuCell Corp的收入贡献最大,创收6.40M,占总收入的99.28%。
KeyAI